Cargando…
Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer
BACKGROUND: Pancreatic cancer is a highly malignant disease with an extremely poor prognosis. Histone deacetylase inhibitors (HDACIs) have shown promising antitumor activities against preclinical models of pancreatic cancer, either alone or in combination with chemotherapeutic agents. In this study,...
Autores principales: | Wang, Guan, He, Jing, Zhao, Jianyun, Yun, Wenting, Xie, Chengzhi, Taub, Jeffrey W., Azmi, Asfar, Mohammad, Ramzi M., Dong, Yan, Kong, Wei, Guo, Yingjie, Ge, Yubin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522644/ https://www.ncbi.nlm.nih.gov/pubmed/23251689 http://dx.doi.org/10.1371/journal.pone.0052095 |
Ejemplares similares
-
Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells
por: Zhao, Jianyun, et al.
Publicado: (2016) -
The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020) -
Expression of Class I and Class II a/b Histone Deacetylase is Dysregulated in Hypertensive Animal Models
por: Kee, Hae Jin, et al.
Publicado: (2017) -
Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia
por: Bai, Guang, et al.
Publicado: (2010) -
The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
por: Khabele, Dineo
Publicado: (2014)